SILK Laser Australia Valuation
Is SLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SLA (A$3.34) is trading above our estimate of fair value (A$1.02)
Significantly Below Fair Value: SLA is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SLA?
Key metric: As SLA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SLA's PE Ratio? | |
|---|---|
| PE Ratio | 24.5x |
| Earnings | AU$7.24m |
| Market Cap | AU$177.42m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.2x |
| Enterprise Value/EBITDA | 12.4x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does SLA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.6x | ||
HLA Healthia | 46.1x | n/a | AU$252.1m |
AHX Apiam Animal Health | 14.6x | n/a | AU$72.1m |
ACL Australian Clinical Labs | 29.1x | 16.0% | AU$697.5m |
FCG Freedom Care Group Holdings | 4.5x | n/a | AU$4.0m |
SLA SILK Laser Australia | 24.5x | 28.9% | AU$177.4m |
Price-To-Earnings vs Peers: SLA is good value based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (25x).
Price to Earnings Ratio vs Industry
How does SLA's PE Ratio compare vs other companies in the Global Healthcare Industry?
| 11 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: SLA is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the Global Healthcare industry average (22.8x).
Price to Earnings Ratio vs Fair Ratio
What is SLA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 24.5x |
| Fair PE Ratio | 29.5x |
Price-To-Earnings vs Fair Ratio: SLA is good value based on its Price-To-Earnings Ratio (24.5x) compared to the estimated Fair Price-To-Earnings Ratio (29.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Doctor Care Anywhere Group
AU$23.5m
Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.
DOC
AU$0.064
7D
-4.5%
1Y
33.3%
CardieX
AU$30.9m
Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.
CDX
AU$0.10
7D
-22.2%
1Y
n/a
Cogstate
AU$166.4m
A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.
CGS
AU$0.96
7D
-2.5%
1Y
-36.9%